Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2018

Open Access 01-12-2018 | Research

Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study

Authors: Jin-Li Wei, Jia-Xin Zhang, De-Yuan Fu

Published in: World Journal of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

The aim of this study was to explore the characteristics and prognostic information of estrogen receptor-positive/progesterone receptor-negative (ER+/PR−) male breast cancer.

Methods

Using the US National Cancer Institute’s Surveillance, Epidemiology, and End Results database, we compared the demographics, clinical characteristics, and outcome of estrogen receptor-positive/progesterone receptor-positive (ER+/PR+) patients with ER+/PR− male breast cancer patients from 1990 to 2010. Two thousand three hundred twenty-two patients with ER+/PR+ tumors and 355 patients with ER+/PR− tumors were included in our study.

Results

ER+/PR− patients were younger (P = 0.008) and more likely to be African American (P < 0.001) while presented with higher histological grade (P < 0.001), larger tumor size (P = 0.010), and more invasion to the lymph nodes (P = 0.034) and distant sites (P < 0.001), thus later stage (P = 0.001). Despite higher chance of receiving chemotherapy (51.0% vs 36.5%, P < 0.001), ER+/PR− patients experienced significantly worse breast cancer-specific survival (BSCC) (P < 0.001) and shorter overall survival (OS) (P = 0.003). Multivariate Cox model confirmed that tumor size, lymph node invasion, metastasis, and surgery were independent prognostic factors of both BSCC and OS for ER+/PR− male breast cancer. Age at diagnosis and chemotherapy were significantly associated with OS but not with BSCC.

Conclusion

ER+/PR− male breast cancer was more aggressive and experienced shorter survival than ER+/PR+ patients. The prognosis was mainly associated with tumor size, lymph node invasion, metastasis, and surgery.
Literature
1.
2.
Stang A, Thomssen C. Decline in breast cancer incidence in the United States: what about male breast cancer? Breast Cancer Res Treat. 2008;112(3):595–6.PubMedCrossRef
3.
Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–17.
4.
Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, et al. Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Mod Pathol. 2017;30(4):509–18.PubMedCrossRef
5.
6.
Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, et al. Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur J Cancer. 2017;82:219–27.PubMedCrossRef
7.
Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S. Molecular characterization and mortality from breast cancer in men. J Clin Oncol. 2018;36(14):1396–404.PubMedPubMedCentralCrossRef
8.
Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, et al. The genomic landscape of male breast cancers. Clin Cancer Res. 2016;22(16):4045–56.PubMedPubMedCentralCrossRef
9.
Rizzolo P, Navazio AS, Silvestri V, Valentini V, Zelli V, Zanna I, et al. Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers. Oncotarget. 2016;7(45):74097–106.PubMedPubMedCentralCrossRef
10.
Abreu MH, Afonso N, Abreu PH, Menezes F, Lopes P, Henrique R, et al. Male breast cancer: looking for better prognostic subgroups. Breast. 2016;26:18–24.PubMedCrossRef
11.
Gu L, Sun B, Zhang L-N, Zhang J, Zhang N. The prognostic value of clinical and pathologic features in nonmetastatic operable male breast cancer. Asian J Androl. 2016;18(1):90.PubMedCrossRef
12.
Choi MY, Lee SK, Lee JE, Park HS, Lim ST, Jung Y, et al. Characterization of Korean male breast cancer using an online nationwide breast-cancer database: matched-pair analysis of patients with female breast cancer. Medicine (Baltimore). 2016;95(16):e3299.CrossRef
13.
Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013;15(4):R68.PubMedPubMedCentralCrossRef
14.
Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232–9.CrossRef
15.
Sineshaw HM, Freedman RA, Ward EM, Flanders WD, Jemal A. Black/white disparities in receipt of treatment and survival among men with early-stage breast cancer. J Clin Oncol. 2015;33(21):2337–44.PubMedCrossRef
16.
Zografos E, Gazouli M, Tsangaris G, Marinos E. The significance of proteomic biomarkers in male breast cancer. Cancer Genomics Proteomics. 2016;13(3):183–90.PubMed
17.
18.
19.
20.
Fentiman IS. Male breast cancer is not congruent with the female disease. Crit Rev Oncol Hematol. 2016;101:119–24.PubMedCrossRef
21.
Shen T, Brandwein-Gensler M, Hameed O, Siegal GP, Wei S. Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. Hum Pathol. 2015;46(11):1776–84.PubMedCrossRef
22.
Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005;23(4):931–2 Author reply 2-3.PubMedCrossRef
23.
Leone JP, Leone J, Zwenger AO, Iturbe J, Vallejo CT, Leone BA. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015;152(3):601–9.PubMedCrossRef
24.
Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51–7.PubMedCrossRef
25.
Madden NA, Macdonald OK, Call JA, Schomas DA, Lee CM, Patel S. Radiotherapy and male breast cancer: a population-based registry analysis. Am J Clin Oncol. 2016;39(5):458–62.PubMedCrossRef
26.
Kwong A, Chau WW, Mang OWK, Wong CHN, Suen DTK, Leung R, et al. Male breast cancer: a population-based comparison with female breast cancer in Hong Kong, Southern China: 1997–2006. Ann Surg Oncol. 2013;21(4):1246–53.PubMedCrossRef
27.
Ndom P, Um G, Bell EM, Eloundou A, Hossain NM, Huo D. A meta-analysis of male breast cancer in Africa. Breast. 2012;21(3):237–41.PubMedCrossRef
28.
Leone JP, Zwenger AO, Iturbe J, Leone J, Leone BA, Vallejo CT, et al. Prognostic factors in male breast cancer: a population-based study. Breast Cancer Res Treat. 2016;156(3):539–48.CrossRef
29.
Shahraki HR, Salehi A, Zare N. Survival prognostic factors of male breast cancer in southern Iran: a LASSO-Cox regression approach. Asian Pac J Cancer Prev. 2015;16(15):6773–7.PubMedCrossRef
30.
Masci G, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist. 2015;20(6):586–92.PubMedPubMedCentralCrossRef
31.
Arslan UY, Oksuzoglu B, Ozdemir N, Aksoy S, Alkis N, Gok A, et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29(2):554–60.PubMedCrossRef
32.
Turashvili G, Gonzalez-Loperena M, Brogi E, Dickler M, Norton L, Morrow M, et al. The 21-gene recurrence score in male breast cancer. Ann Surg Oncol. 2018;25(6):1530–5.PubMedCrossRef
Metadata
Title
Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study
Authors
Jin-Li Wei
Jia-Xin Zhang
De-Yuan Fu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1539-7

Other articles of this Issue 1/2018

World Journal of Surgical Oncology 1/2018 Go to the issue

Case report

Calcifying nested stromal epithelial tumor of the liver in a patient with Klinefelter syndrome: a case report and review of the literature

Correspondence

Letter to the editor: is HIF-1α a viable prognostic indicator in OSCC? A critical review of a meta-analysis study

Research

Carotid artery infusion via implantable catheters for squamous cell carcinoma of the tonsils

Review

Schwannoma of the colon and rectum: a systematic literature review

Research

Significance of poor performance status after resection of colorectal liver metastases

Research

Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis